Carl Dambkowski - 04 Mar 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Role
Chief Medical Officer
Signature
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski
Issuer symbol
APGE
Transactions as of
04 Mar 2026
Net transactions value
-$390,825
Form type
4
Filing time
06 Mar 2026, 20:00:10 UTC
Previous filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dambkowski Carl Chief Medical Officer C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski 06 Mar 2026 0001983476

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGE Common Stock Options Exercise +4,125 +2% $22.86* 215,273 04 Mar 2026 Direct
transaction APGE Common Stock Sale $226,814 -3,225 -1.5% $70.33 212,048 04 Mar 2026 Direct F1, F2
transaction APGE Common Stock Sale $149,358 -2,075 -0.98% $71.98 209,973 04 Mar 2026 Direct F1, F3
transaction APGE Common Stock Sale $14,652 -200 -0.1% $73.26 209,773 04 Mar 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGE Stock Option (Right to Buy) Options Exercise -4,125 -3% $0.000000* 131,290 04 Mar 2026 Common Stock 4,125 $22.86 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $70.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.51 to $72.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.20 to $73.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.